Canaccord raised the firm’s price target on Insulet (PODD) to $399 from $353 and keeps a Buy rating on the shares. The firm updated its model to reflect both updated revenue guidance and commentary from recent investor conferences. Canaccord continues to believe Insulet is well positioned to win in the insulin pump market with its differentiated form factor and first mover advantage in the T2D market.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Trump announces $15B libel suit against New York Times: Morning Buzz
- Trump announces $15 libel suit against New York Times: Morning Buzz
- Insulet Appoints New CFO Amid Revenue Growth
- Insulet expects to exceed Q3 revenue view of up 22%-25%
- Insulet CFO Ana Maria Chadwick to leave role, Flavia Pease to succeed